Alzheimer's disease: Targeting the Cholinergic System
Talita H. Ferreira-Vieira,Isabella M. Guimaraes,Flavia Rodrigues da Silva,Fabiola M. Ribeiro +3 more
Reads0
Chats0
TLDR
Synthesis of cholinergic neurons located in the basal forebrain, including the neurons that form the nucleus basalis of Meynert, are severely lost in Alzheimer’s disease, and drugs that act on the choline system represent a promising option to treat AD patients.Abstract:
Acetylcholine (ACh) has a crucial role in the peripheral and central nervous systems. The enzyme choline acetyltransferase (ChAT) is responsible for synthesizing ACh from acetyl-CoA and choline in the cytoplasm and the vesicular acetylcholine transporter (VAChT) uptakes the neurotransmitter into synaptic vesicles. Following depolarization, ACh undergoes exocytosis reaching the synaptic cleft, where it can bind its receptors, including muscarinic and nicotinic receptors. ACh present at the synaptic cleft is promptly hydrolyzed by the enzyme acetylcholinesterase (AChE), forming acetate and choline, which is recycled into the presynaptic nerve terminal by the high-affinity choline transporter (CHT1). Cholinergic neurons located in the basal forebrain, including the neurons that form the nucleus basalis of Meynert, are severely lost in Alzheimer's disease (AD). AD is the most ordinary cause of dementia affecting 25 million people worldwide. The hallmarks of the disease are the accumulation of neurofibrillary tangles and amyloid plaques. However, there is no real correlation between levels of cortical plaques and AD-related cognitive impairment. Nevertheless, synaptic loss is the principal correlate of disease progression and loss of cholinergic neurons contributes to memory and attention deficits. Thus, drugs that act on the cholinergic system represent a promising option to treat AD patients.read more
Citations
More filters
Journal ArticleDOI
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Zeinab Breijyeh,Rafik Karaman +1 more
TL;DR: Currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds are discussed.
Journal ArticleDOI
The Effects of Acute Exercise on Mood, Cognition, Neurophysiology, and Neurochemical Pathways: A Review
Julia C. Basso,Wendy A. Suzuki +1 more
TL;DR: The cognitive and behavioral changes that occur with acute exercise in humans and animal model studies documenting the wide range of neurophysiological and neurochemical alterations that occur after a single bout of exercise are summarized.
Journal ArticleDOI
History and progress of hypotheses and clinical trials for Alzheimer’s disease
TL;DR: It is proposed that fluoxetine, a selective serotonin reuptake inhibitor, has the potential to treat AD and the combination of hypometabolism and autophagy deficiency is likely to be a causative factor for AD.
Journal ArticleDOI
Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders.
Ghulam Hussain,Azhar Rasul,Haseeb Anwar,Nimra Aziz,Aroona Razzaq,Wei Wei,Wei Wei,Muhammad Ali,Jiang Li,Xiaomeng Li +9 more
TL;DR: The present article reviews the potential efficacy of plant-derived alkaloids, which possess potential therapeutic effects against several NDDs including Alzheimer's disease, Huntington disease, Parkinson's disease (PD), Epilepsy, Schizophrenia, and stroke.
Journal ArticleDOI
Heme Cofactor-Resembling Fe–N Single Site Embedded Graphene as Nanozymes to Selectively Detect H2O2 with High Sensitivity
Min Su Kim,Junsang Lee,Hye Su Kim,Ara Cho,Kyu Hwan Shim,Thao Nguyen Le,Seong Soo A. An,Jeong Woo Han,Moon Il Kim,Jinwoo Lee +9 more
TL;DR: Based on the high and selective peroxidase‐like activity of Fe–N‐rGO, trace amounts of H2O2 produced from the enzymatic reactions from acetylcholine and cancerous cells are successfully quantified with high sensitivity and selectivity and are expected to encourage studies on the rational design of nanozymes pursuing the active site structure of natural enzymes.
References
More filters
Journal ArticleDOI
Global prevalence of dementia: a Delphi consensus study
Cleusa P. Ferri,Martin Prince,Carol Brayne,Henry Brodaty,Laura Fratiglioni,Mary Ganguli,Kathleen S. Hall,Kazuo Hasegawa,Hugh C. Hendrie,Yueqin Huang,Anthony F. Jorm,Colin Mathers,Paulo Rossi Menezes,Elizabeth Rimmer,Marcia Scazufca +14 more
TL;DR: Detailed estimates of dementia prevalence for each world region are believed to constitute the best currently available basis for policymaking, planning, and allocation of health and welfare resources.
Journal ArticleDOI
Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
George G. Glenner,Caine W. Wong +1 more
TL;DR: A purified protein derived from the twisted beta-pleated sheet fibrils in cerebrovascular amyloidosis associated with Alzheimer's disease has been isolated and Amino acid sequence analysis and a computer search reveals this protein to have no homology with any protein sequenced thus far.
Journal ArticleDOI
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Jie Kang,H. G. Lemaire,A. Unterbeck,J. M. Salbaum,Colin L. Masters,K.-H. Grzeschik,Gerd Multhaup,Konrad Beyreuther,Benno Müller-Hill +8 more
TL;DR: An apparently full-length complementary DNA clone coding for the A4 polypeptide is isolated and sequenced and suggests that the cerebral amyloid deposited in Alzheimer's disease and aged Down's syndrome is caused by aberrant catabolism of a cell-surface receptor.
Journal ArticleDOI
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.
Robert D. Terry,Eliezer Masliah,David P. Salmon,Nelson Butters,Richard DeTeresa,Robert Hill,Lawrence A. Hansen,Robert Katzman +7 more
TL;DR: Both linear regressions and multivariate analyses correlating three global neuropsychological tests with a number of structural and neurochemical measurements performed on a prospective series of patients with Alzheimer's disease and 9 neuropathologically normal subjects reveal very powerful correlations with all three psychological assays.
Journal ArticleDOI
Alzheimer's Disease Is a Synaptic Failure
TL;DR: Mounting evidence suggests that this syndrome begins with subtle alterations of hippocampal synaptic efficacy prior to frank neuronal degeneration, and that the synaptic dysfunction is caused by diffusible oligomeric assemblies of the amyloid β protein.
Related Papers (5)
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
John Hardy,Dennis J. Selkoe +1 more